newsfilter
← Latest News
PR Newswire·

Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ - Nova Mentis Life Science Corp. (CSE:NOVA) (FSE: HN3Q) (OTCQB:NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagno